Teva has a terrible balance sheet, and while it's current market cap is less than 50% of what it recently paid for Actavis the major generic's are in bad shape. For the first time they are being told what they can charge.
It wouldn't surprise me if Private Equity takes some divisions.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.